Global Type 1 Diabetes Market 2014-2018

1型糖尿病のグローバル市場動向(2014-2018)

◆タイトル:Global Type 1 Diabetes Market 2014-2018
◆商品コード:IRTNTR3537
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年5月30日
◆ページ数:85
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥316,400見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"1型糖尿病のグローバル市場動向(2014-2018)"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況等の情報をお届けいたします。

About Type 1 Diabetes
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against self-insulin producing cells. This, in turn, hampers the body’s ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes T1D differs from the more common form of diabetes mellitus, Type 2 diabetes, as people with Type 2 diabetes do produce insulin. T1D accounts for only 5-15 percent of the total diabetic cases and is usually reported in children and adolescents. T1D was formerly known as juvenile diabetes. T1D management relies on providing symptomatic relief and improving quality of life.
TechNavio’s analysts forecast the Global Type 1 Diabetes Market will grow at a CAGR of 6.9 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Type 1 Diabetes Market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of various type 1 diabetes management drugs, which includes insulin-based replacement products and amylin analogues.
TechNavio’s report, the Global Type 1 Diabetes Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Type 1 Diabetes market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Astrazeneca plc
• Eli Lilly and Co.
• Novo Nordisk A/S
• Sanofi-Aventis US LLC
Other Prominent Vendors

• Biodel Inc.
• Diamyd Medical AB
• DiaVacs Inc.
• Generex Biotechnology Corp.
• Lexicon Pharmaceuticals Inc.
• Macrogenics Inc.
• MannKind Corp.
• Osiris Therapeutics Inc.
• Tolerion Inc.
• XOMA Corp.

Key Market Driver
• Increasing Global Type 1 Diabetic Population.
• For a full, detailed list, view our report.
Key Market Challenge
• Side Effects of Current Therapies.
• For a full, detailed list, view our report.
Key Market Trend
• Focus on Emerging Markets.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Global Market Share by Products
08. Product Portfolio
09. Clinical Pipeline Portpolio
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Future Vendors Expected to Tap the Market

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Type 1 Diabetes Drugs Market 2013-2018 (US$ million)
Exhibit 3: Global Market Share of Diabetes Drugs 2013 (US$ million)
Exhibit 4: Global Type 1 Diabetes Market by Geographical Segmentation 2013
Exhibit 5: Incidence and Prevalence of Type1 Diabetes in Children (0-14 Years) 2013 (in thousands)
Exhibit 6: Market Share of Vendors in Global Type 1 Diabetes Market (in Percent)
Exhibit 7: Revenue Share of Novo Nordisk’s Insulin Products (in Percent)
Exhibit 8: Novo Nordisk’s Insulin Products Revenue Segmentation by Geography (in Percentage)
Exhibit 9: Geography Wise Revenue of Novo Nordisk’s Insulin Products (US$ million)
Exhibit 10: Eli Lilly’s Insulin Products Revenue Segmentation by Geography (in Percentage)
Exhibit 11: Geography Wise Revenue of Eli Lilly’s Insulin Products (US$ million)
Exhibit 12: Sanofi’s Insulin Products Revenue Segmentation by Geography (in Percentage)



【掲載企業】

Astrazeneca plc , Eli Lilly and Co., Novo Nordisk A/S, Sanofi-Aventis US LLC, Biodel Inc., Diamyd Medical AB, DiaVacs Inc., Generex Biotechnology Corp., Lexicon Pharmaceuticals Inc., Macrogenics Inc., MannKind Corp., Osiris Therapeutics Inc., Tolerion Inc., XOMA Corp.

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[1型糖尿病のグローバル市場動向(2014-2018)] (Global Type 1 Diabetes Market 2014-2018 / IRTNTR3537)販売に関する免責事項
[1型糖尿病のグローバル市場動向(2014-2018)] (Global Type 1 Diabetes Market 2014-2018 / IRTNTR3537)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆